Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced that Biopharm R&D at GlaxoSmithKline (GSK) has selected Genedata BiologicsTM as a key R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.
The system records, manages, and processes data from GSK's diverse antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies, including proprietary ones. In addition, Genedata Biologics helps to improve data quality, improve efficiency through upload and export of instrument data, increase experimental throughput, and streamline workflows.
Genedata supports the deployment and roll-out of the Genedata Biologics system, its integration into GSK's R&D environment, and its use of Biopharm's high-throughput automation platforms. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats such as GSK's domain antibodies and other proprietary molecules and technologies.
As an integrated and scalable IT platform, Genedata Biologics makes it easy to share results across many groups involved in R&D projects. The system's built-in business logic supports the full diversity of GSK's complex and evolving antibody discovery processes.
"We are honored to have GSK, a global leader in biopharmaceuticals, chose Genedata Biologics as the platform to support their biopharmaceutical R&D processes," said Dr. Othmar Pfannes, CEO of Genedata. "The collaboration with GSK is another milestone on our path to establish Genedata Biologics worldwide as the platform of choice to streamline the discovery and development of novel biopharmaceuticals. We will continue to expand the platform to meet the quickly emerging new requirements in support of this highly innovative and important field."